Eli Lilly is selling higher-dose vials of Zepbound at a lower price to boost weight loss drug access
Eli Lilly on Tuesday released higher doses of its weight loss drug Zepbound in single-dose vials at as much as half its usual monthly list price to reach more patients without insurance coverage for ...
INDIANAPOLIS, Feb. 25, 2025 /PRNewswire/ -- Today Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the new ...
Ro said it will offer a "complete end-to-end" experience on a single platform and app, allowing eligible patients to receive a diagnosis and a prescription for Zepbound and have vials of the drug ...
Zepbound and Mounjaro have been shown to yield greater weight loss than Wegovy or Ozempic. The dual mechanism of tirzepatide, ...
With a valid prescription, patients can access the starting dose of Zepbound single-dose vial (2.5 mg) for as low as $299 per month. “Far too many people who need obesity treatments still face cost ...
Six months after Eli Lilly began selling discounted vials of its blockbuster weight loss drug Zepbound, the company expanded the offering Feb. 25 to include cheaper, high-dose Zepbound vials. A ...
On Tuesday, Eli Lilly And Co (NYSE:LLY) launched 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the new Zepbound Self Pay Journey Program. Eli Lilly also reduced ...
Walmart, with nearly 4,600 pharmacies nationwide, will serve as the first in-store pickup pharmacy for LillyDirect's self-pay single-dose vials Strategic collaboration marks the first time patients ...
The latest self-pay markdowns mean that all Zepbound strengths will soon be available for $499 per month or less, according to Lilly. (Eli Lilly) Eli Lilly is unleashing self-pay discounts across the ...
Eli Lilly is unleashing new ammunition in its fight against cheaper, compounded versions of its obesity blockbuster Zepbound. The Indiana-based drugmaker is slashing the prices of its 2.5 mg ...
New pricing aims to attract cash-paying customers via LillyDirect Hims & Hers warns it may stop selling compounded version of Novo Nordisk weight-loss drugs Telehealth firms' shares fall The move ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results